Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Excision BioTherapeutics logo — Developing CRISPR-based therapies intended to cure viral inf...

Excision BioTherapeutics

Developing CRISPR-based therapies intended to cure viral infectious diseases.

Founded 2015 United States Watertown, United States 24 employees Grant Total: $77.60M Biotechnology, Health Care +1

General Information

Company Name Excision BioTherapeutics
Founded Year 2015
Location United States Watertown, United States
Employees 24
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Excision BioTherapeutics. To contact Excision BioTherapeutics, visit excision.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Excision BioTherapeutics compare?

A PDF of Excision BioTherapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Excision BioTherapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Excision BioTherapeutics

Excision BioTherapeutics, founded in 2015, is a pivotal player in the Biotechnology industry, specifically targeting Health Care and Health and Wellness. Based in the United States, the company is pioneering the development of CRISPR-based therapies with the compelling objective of curing viral infectious diseases.

Their strategic mission is centered around creating advanced gene editing therapeutics aimed at addressing the substantial medical needs for treatments of life-threatening viral infections. This initiative promises to transform the lives of affected individuals globally by providing safe and efficacious medications.

Excision BioTherapeutics recently secured a $6.85M grant investment as of September 29, 2022, with financial backing from the California Institute for Regenerative Medicine. This bolsters their capital for advancing their groundbreaking therapies and underscores significant interest from reputable investors within the sector.

Business keywords: CRISPR, Gene Editing, Infectious Diseases, Viral Infections, Therapeutics Development, Life-threatening Diseases, Genetic Medicine, Human Health, Gene Therapy, Biomedical Research, Disruptive Technology, Medical Innovation, Excision Approach, Advanced Therapeutics

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $6.85M 1
California Institute for Regenerative Medicine
29 Sep 2022
Venture Round $60.00M 10
GreatPoint Ventures Anzu Partners Norwest Venture Partners
GreatPoint Ventures, Anzu Partners +8
17 Feb 2021
Series A Undisclosed 10
GreatPoint Ventures Madrona Arch Venture Partners
GreatPoint Ventures, Madrona +8
02 Feb 2021
Debt Financing Undisclosed 1
Ben Franklin Technology Partners of Southeastern Pennsylvania
Ben Franklin Technology Partners of Southeastern Pennsylvania
08 Sep 2020
Seed Round Undisclosed 1
Bioverge Ventures
Bioverge Ventures
20 Mar 2020
Seed Round $750.00K 4
Gaingels SandHill Angels
Gaingels, SandHill Angels +2
20 Dec 2019
Seed Round $10.00M 7
Gaingels Norwest Venture Partners Oakhouse Partners
Gaingels, Norwest Venture Partners +5
06 Sep 2017
Seed Round Undisclosed -
01 Jul 2017

Excision BioTherapeutics Alternatives & Competitors

View All Alternatives
Excision BioTherapeutics vs
AN2 Therapeutics
AN2 Therapeutics United States

Developing therapies for rare, chronic, and serious infectious diseases

Grant
35 employees
Biotechnology, Health Care
Excision BioTherapeutics vs
Alia Therapeutics
Alia Therapeutics Italy

On-target gene therapies

Seed
15 employees
Biotechnology, Health and Wellness
Excision BioTherapeutics vs
Kimer Med
Kimer Med New Zealand

We're developing a family of broad-spectrum antivirals to address hundreds of currently untreatable...

Seed
9 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Excision BioTherapeutics

Developing CRISPR-based therapies intended to cure viral infectious diseases.
Excision BioTherapeutics was founded in 2015.
Excision BioTherapeutics is headquartered in Watertown, United States.
Excision BioTherapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on CRISPR, Gene Editing, Infectious Diseases and Viral Infections.
Excision BioTherapeutics has approximately 24 employees.
Excision BioTherapeutics has completed 8 funding rounds, raising a total of $77.60M. The latest funding stage is Grant.
Top alternatives and competitors to Excision BioTherapeutics include AN2 Therapeutics, Alia Therapeutics, Kimer Med, EmendoBio, AveXis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Excision BioTherapeutics and AN2 Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Excision BioTherapeutics, https://bouncewatch.com/company/excision-biotherapeutics, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout